| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
This study was to determine the molecular mechanism responsible for the refractory FLT3 mutated acute myeloid leukemia. Using the mRNA microarray screening, we identified a transcriptional factor Runx1 as a candidate molecule responsible for the resistance of the FLT3 mutated acute myeloid leukemia. Our subsequent analyses validate that Runx1 is indeed involved and modulate resistance regulated by chemokine Cxcl12 in FLT3 mutated acute myeloid leukemia cells. We identified that changes in expression level in FLT3 mutated acute myeloid leukemia cells, which was dependent on the magnitude of Cxcl12/Cxcr4 signaling, regulates resistance of FLT3 mutated acute myeloid leukemia against FLT3 inhibitors. This study suggest that Runx1 represents potential target for the treatment of FLT3 mutated acute myeloid leukemia that are refractory against FLT3 inhibitors.
|
